Fry, David W.

Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts

Fry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics

Cancer-related Molecular PathwaysAdvanced Breast Cancer Therapies

Cited by 1,236

A Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase

Fry, D. W., Kraker, A. J., McMichael, A., Ambroso, L. A., Nelson, J. M., Leopold, W. R., Connors, R. W., & Bridges, A. J. (1994) · Science

HER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations

Cited by 806

Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6

Toogood, P. L., Harvey, P. J., Repine, J. T., Sheehan, D. J., VanderWel, S. N., Zhou, H., Keller, P. R., McNamara, D. J., Sherry, D., Zhu, T., et al. (2005) · Journal of Medicinal Chemistry

Heterocyclic Compound Synthesis and BioactivityAdvanced Breast Cancer Therapies

Cited by 513

Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor

Gonzales, A. J., Hook, K. E., Althaus, I. W., Ellis, P. A., Trachet, E., Delaney, A. M., Harvey, P. J., Ellis, T. A., Amato, D. M., Nelson, J. M., et al. (2008) · Molecular Cancer Therapeutics

HER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations

Cited by 226